{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Frantz S"],"funding":["DFG","CRC1525"],"pagination":["2549-2561"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9336586"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(27)"],"pubmed_abstract":["Most patients survive acute myocardial infarction (MI). Yet this encouraging development has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend to have more comorbidities worsening economic strain on healthcare systems and impeding effective medical management. The heart's pathological changes in structure and/or function, termed myocardial remodelling, significantly impact on patient outcomes. Risk factors like diabetes, chronic obstructive pulmonary disease, female sex, and others distinctly shape disease progression on the 'road to HF'. Despite the availability of HF drugs that interact with general pathways involved in myocardial remodelling, targeted drugs remain absent, and patient risk stratification is poor. Hence, in this review, we highlight"],"journal":["European heart journal"],"pubmed_title":["Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies."],"pmcid":["PMC9336586"],"funding_grant_id":["KFO311","453989101"],"pubmed_authors":["Frantz S","Hundertmark MJ","Bauersachs J","Bengel FM","Schulz-Menger J"],"additional_accession":[]},"is_claimable":false,"name":"Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.","description":"Most patients survive acute myocardial infarction (MI). Yet this encouraging development has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend to have more comorbidities worsening economic strain on healthcare systems and impeding effective medical management. The heart's pathological changes in structure and/or function, termed myocardial remodelling, significantly impact on patient outcomes. Risk factors like diabetes, chronic obstructive pulmonary disease, female sex, and others distinctly shape disease progression on the 'road to HF'. Despite the availability of HF drugs that interact with general pathways involved in myocardial remodelling, targeted drugs remain absent, and patient risk stratification is poor. Hence, in this review, we highlight","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-05-29T16:11:11.109Z","creation":"2025-04-04T08:07:52.294Z"},"accession":"S-EPMC9336586","cross_references":{"pubmed":["35511857"],"doi":["10.1093/eurheartj/ehac223"]}}